20/20 Biolabs is trading 5.42% down at $0.52 after its August 17, 2026, second-quarter report showed revenue growth but a wider net loss.
- Revenue rose 36.5% to $0.7 million, while gross margin expanded to 41.7%.
- Net loss reached $1.5 million, including approximately $0.7 million in non-cash charges.
- Nasdaq Composite futures fell 1.26%, adding pressure to the pre-market decline, particularly across technology stocks.